A Randomized Study of LP-128 Capsules vs. Placebo to Evaluate Safety, Tolerability and Pharmacokinetics in Healthy Subjects
Latest Information Update: 08 Apr 2025
At a glance
- Drugs LP-128 (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Guangzhou Lupeng Pharmaceutical
Most Recent Events
- 03 Apr 2025 Planned End Date changed from 31 Dec 2024 to 30 Dec 2026.
- 03 Apr 2025 Planned primary completion date changed from 30 Dec 2024 to 30 Sep 2026.
- 26 Feb 2024 Planned End Date changed from 31 Dec 2023 to 31 Dec 2024.